Shon JH - Search Results

1

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim MK, Cha IJ, Hyun MH, Shin JG. Kim KA, et al. Among authors: shon jh. Clin Pharmacol Ther. 2002 Jul;72(1):90-9. doi: 10.1067/mcp.2002.126176. Clin Pharmacol Ther. 2002. PMID: 12152007 Clinical Trial.

2

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.

Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG. Shon JH, et al. Pharmacogenetics. 2002 Mar;12(2):111-9. doi: 10.1097/00008571-200203000-00005. Pharmacogenetics. 2002. PMID: 11875365 Clinical Trial.

3

Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes.

Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. Kim KA, et al. Among authors: shon jh. Drug Metab Dispos. 2003 Oct;31(10):1227-34. doi: 10.1124/dmd.31.10.1227. Drug Metab Dispos. 2003. PMID: 12975331

4

Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

Shon JH, Yoon YR, Kim MJ, Kim KA, Lim YC, Liu KH, Shin DH, Lee CH, Cha IJ, Shin JG. Shon JH, et al. Br J Clin Pharmacol. 2005 May;59(5):552-63. doi: 10.1111/j.1365-2125.2005.02364.x. Br J Clin Pharmacol. 2005. PMID: 15842554 Free PMC article.

5

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.

Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG. Shon JH, et al. Clin Pharmacol Ther. 2005 Aug;78(2):191-201. doi: 10.1016/j.clpt.2005.04.012. Clin Pharmacol Ther. 2005. PMID: 16084853 Clinical Trial.

6

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.

Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, Shin JG. Park JY, et al. Among authors: shon jh. Clin Pharmacol Ther. 2006 Jun;79(6):590-9. doi: 10.1016/j.clpt.2006.02.008. Clin Pharmacol Ther. 2006. PMID: 16765147 Clinical Trial.

7

Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.

Cho H, Choi MK, Cho DY, Yeo CW, Jeong HE, Shon JH, Lee JY, Shin JS, Cho M, Kim DY, Shin JG. Cho H, et al. Among authors: shon jh. J Clin Pharmacol. 2012 Jul;52(7):976-84. doi: 10.1177/0091270011408611. Epub 2011 May 18. J Clin Pharmacol. 2012. PMID: 21593280 Clinical Trial.

8

Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.

Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, Park CW, Shin SG, Flockhart DA, Shin JG. Yoon YR, et al. Among authors: shon jh. Clin Pharmacol Ther. 2000 May;67(5):567-76. doi: 10.1067/mcp.2000.106128. Clin Pharmacol Ther. 2000. PMID: 10824636

9

Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.

Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG. Yoon YR, et al. Among authors: shon jh. Br J Clin Pharmacol. 2001 Mar;51(3):277-80. doi: 10.1046/j.1365-2125.2001.00340.x. Br J Clin Pharmacol. 2001. PMID: 11298075 Free PMC article.

10

Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.

Liu KH, Kim MJ, Shon JH, Moon YS, Seol SY, Kang W, Cha IJ, Shin JG. Liu KH, et al. Among authors: shon jh. Xenobiotica. 2005 Jan;35(1):27-38. doi: 10.1080/00498250400026472. Xenobiotica. 2005. PMID: 15788366

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters